格隆汇9月26日丨长风药业(02652.HK)发布公告，公司拟全球发售4119.8万股H股，中国香港发售股份 412万股，国际发售股份3707.8万股；2025年9月26日至10月2日招股；发售价将为每股发售股份14.75港 元，每手买卖单位为500股，中信证券及招银国际为联席保荐人；预期股份将于2025年10月8日开始在联 交所买卖。 如今，集团正在推进中国、美国及╱或欧洲等主要市场和东南亚及南美等新兴市场的20多款候选产品的 开发。集团积极探索如脂质体及siRNA在内的创新吸入制剂剂型，并将治疗领域扩展至包括中枢神经系 统(CNS)疾病及抗感染在内的新疾病领域。集团也在开发新的治疗方法，如支气管内活瓣(EBV)，并为 治疗特发性肺纤维化(IPF)及肺动脉高压(PAH)等严重影响患者生活的疾病开发潜在的同类首创或中国首 创治疗方法。 假设发售价为每股股份14.75港元，集团估计将收取全球发售所得款项净额约5.254亿港元。集团目前拟 将该等所得款项净额用作以下用途：约40.0%将用于为集团国内及国际的吸入制剂候选产品的持续研 发、临床开发及商业化提供资金；约20.0%将用于为集团多个管线计划及技术的临床前研 ...

Core Viewpoint - Changfeng Pharmaceutical Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with CITIC Securities and China Merchants Jinling International as joint sponsors [1]. Group 1: Company Overview - Changfeng Pharmaceutical focuses on the research, development, production, and commercialization of inhalation technology and inhalation drugs, primarily targeting respiratory diseases [3]. - The company has developed a diverse product portfolio that addresses a wide range of patients, medical specialties, and treatment areas [3]. Group 2: Key Products and Market Position - CF017, an inhalation solution of budesonide for treating bronchial asthma, is the company's first approved product and the best-selling inhalation drug category in China. It was approved in May 2021 and has since been included in China's centralized procurement (VBP) plan, leading to market growth [3]. - By 2024, CF017 is projected to capture approximately 16% of the Chinese budesonide inhalation drug market by sales volume [3]. - The company is advancing over 20 candidate products for global development in major markets like China and the U.S., as well as emerging markets in Southeast Asia and South America [3]. Group 3: Recent Developments and Financial Performance - In May 2024, the company successfully obtained FDA approval for GW006, an aerosol solution of afromoterol for treating chronic obstructive pulmonary disease (COPD) [4]. - CF018, the first approved nasal spray for moderate to severe allergic rhinitis in China, has penetrated over 500 hospitals and medical institutions after being included in the 2023 National Medical Insurance Drug List [5]. - The commercialization of CF017 significantly boosted the company's revenue, with revenues of approximately RMB 349 million, RMB 556 million, and an estimated RMB 608 million for the years 2022, 2023, and 2024, respectively [5][6]. - The gross profit for the same years was approximately RMB 267 million, RMB 458 million, and RMB 491 million, indicating a strong growth trajectory [5][6].